1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)

Peter K. H. Lau; Breon Feran; Lorey Smith; Arian Lasocki; Ramyar Molania; Kortnye Smith; Alison M. Weppler; Christopher Angel; Damien Kee; Prachi Bhave; Belinda Lee; Han Xian Aw Yeang; Ismael A. Vergara; David L. Kok; Katharine J. Drummond; Paul J. Neeson; Karen E. Sheppard; Anthony T. Papenfuss; Shahneen Sandhu; Grant A. McArthur

doi:10.1016/j.annonc.2020.08.1203

Article2021

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J. Young, Amir Iravani, Hanxian Aw Yeang, Ismael A. Vergara, David L. Kok, Kate Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Benjamin Solomon, Shahneen Sandhu, Grant A. McArthur

Article2014

Response of BRAF -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Tiffany J. Parmenter, Margarete Kleinschmidt, Kathryn M. Kinross, Simon T. Bond, Jason Li, Mohan R. Kaadige, Aparna D. Rao, Karen E. Sheppard, Willy Hugo, Gulietta M. Pupo, Richard B. Pearson, Sean L. McGee, Georgina V. Long, Richard A Scolyer, Helen Rizos, Roger S. Lo, Carleen Cullinane, Donald E. Ayer, Antoni Ribas, Ricky W. Johnstone, Rodney J. Hicks, Grant A. McArthur

Preprint2023

Supplementary Data 1 from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Tiffany J. Parmenter, Margarete Kleinschmidt, Kathryn M. Kinross, Simon T. Bond, Jason Li, Mohan R. Kaadige, Aparna Rao, Karen E. Sheppard, Willy Hugo, Gulietta M. Pupo, Richard B. Pearson, Sean L. McGee, Georgina V. Long, Richard A Scolyer, Helen Rizos, Roger S. Lo, Carleen Cullinane, Donald E. Ayer, Antoni Ribas, Ricky W. Johnstone, Rodney J. Hicks,

Preprint2023

Supplementary Data 1 from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Tiffany J. Parmenter, Margarete Kleinschmidt, Kathryn M. Kinross, Simon T. Bond, Jason Li, Mohan R. Kaadige, Aparna Rao, Karen E. Sheppard, Willy Hugo, Gulietta M. Pupo, Richard B. Pearson, Sean L. McGee, Georgina V. Long, Richard A Scolyer, Helen Rizos, Roger S. Lo, Carleen Cullinane, Donald E. Ayer, Antoni Ribas, Ricky W. Johnstone, Rodney J. Hicks,

Article2022

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

James S. Wilmott, Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M. Ferguson, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Lisa H. Butterfield, Richard A Scolyer, John M. Kirkwood, Georgina V. Long, Michael A. Davies

1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)

Discussion(0)

Related publications

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Supplementary Data 1 from Response of <i>BRAF</i>-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Supplementary Data 1 from Response of <i>BRAF</i>-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)

Discussion(0)

Related publications

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Supplementary Data 1 from Response of &lt;i&gt;BRAF&lt;/i&gt;-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Supplementary Data 1 from Response of &lt;i&gt;BRAF&lt;/i&gt;-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Supplementary Data 1 from Response of <i>BRAF</i>-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Supplementary Data 1 from Response of <i>BRAF</i>-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis